¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Magnetic Resonance Imaging Contrast Agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • magnetic moment nulling
    ÀÚ±â¸ð¸àÆ®¹«È¿È­
  • magnetic permeability
    ÀÚ±âÅõ°úµµ
  • magnetic pole
    ÀÚ±Ø, ÀÚ±â±Ø
  • magnetic shielding
    ÀÚ±âÀåÂ÷Æó
  • magnetic stirrer
    ÀÚ¼®Á£°³, Àڷ±³¹Ý±â
  • magnetic susceptibility
    ÀڱⰨ¼öÀ², ÀÚÈ­À², ´ëÀÚÀ²
  • magnetic susceptibility artifact
    ÀÚÈ­À²Àΰø¹°
  • magnetic susceptibility gradient
    ÀÚ±âÈ­À²±â¿ï±â
  • relative magnetic permeability
    »ó´ëÀÚ±âÅõ°ú·Â
  • static magnetic field
    Á¤ÀÚ±âÀå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • gradient magnetic field
    ±â¿ï±âÀÚ±âÀå, °æ»çÀÚ±âÀå
  • magnetic field
    ÀÚ±âÀå
  • magnetic fringe field
    ÁÖº¯ÀÚ±âÀå
  • magnetic induction field
    ÀÚ±âÀ¯µµÀÚ±âÀå
  • static magnetic field
    Á¤ÀÚ±âÀå
  • magnetic field gradient
    ÀÚÀå±â¿ï±â
  • magnetic susceptibility gradient
    ÀÚ±âÈ­À²±â¿ï±â
  • magnetic induction
    ÀÚ±âÀ¯µµ
  • magnetic intensity
    ÀÚÀå°­µµ
  • magnetic isocenter
    Àڱ⵿½É
  • magnetic memory
    ÀÚ±â±â¾ï
  • magnetic permeability
    ÀÚ±âÅõ°úµµ
  • magnetic pole
    ÀÚ±Ø
  • magnetic shielding
    ÀÚ±âÀåÂ÷Æó
  • magnetic stirrer
    ÀÚ¼®Á£°³, Àڷ±³¹Ý±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • magnetic oil
    ÀÚ±âÀ¯(í¸Ñ¨êú).
  • magnetic permeability
    ÀÚ±â Åõ°úµµ
  • magnetic pole
    ÀÚ±Ø
  • magnetic property
    ÀÚ¼º
  • magnetic shielding
    ÀÚ±â(Àå) Â÷Æó
  • magnetic stirrer
    ÀÚ¼®Á£°Ô, Àڷ±³¹Ý±â
  • magnetic susceptibility
    ÀÚ±âÈ­À²
  • magnetic susceptibility artefact
    ÀÚ±âÈ­À² Àΰø¹°
  • magnetic susceptibility gradient
    ÀÚ±âÈ­À² °æ»ç
  • magnetic susceptibility variation
    ÀÚ±âÈ­À² º¯ÀÌ
  • main magnetic field inhomogenity
    ÁÖ ÀÚÀå ºñ±ÕÁú¼º
  • relative magnetic permeability
  • static magnetic field
    Á¤ÀÚÀå
  • volume magnetic susceptibility
    ¿ëÀû ÀÚÈ­À²
  • amphoric resonance
    °øµ¿(¼º) °ø¸íÀ½
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • dynamic imaging
    ¿ªµ¿Àû¿µ»ó
  • echo planar imaging [=EPI]
    ¿¡ÄÚÆò¸é¿µ»ó
  • fast Fourier imaging
    °í¼ÓFourier¿µ»ó
  • fast imaging technique
    °í¼Ó¿µ»ó±â¹ý
  • fast imaging with steady state precession [=FISP]
    Ç×Á¤»óż¼Â÷¿îµ¿À» ÀÌ¿ëÇÑ °í¼Ó¿µ»ó
  • fast scan imaging
    °í¼Ó½ºÄµ¿µ»ó
  • fast spin echo imaging
    °í¼Ó½ºÇÉ¿¡ÄÚ¿µ»ó
  • first-pass MR imaging
    ÀÏÂ÷Åë°úÀÚ±â°ø¸í¿µ»ó
  • Fourier imaging
    Fourier¿µ»ó
  • fractional echo imaging
    ºÐÇÒ¿¡ÄÚ¿µ»ó
  • frequency modulation imaging
    Á֯ļöº¯Á¶¿µ»ó
  • functional brain imaging
    ±â´ÉÀû³ú¿µ»ó
  • gradient acquisition imaging
    °æ»çȹµæ¿µ»ó
  • gradient echo [=GRE] imaging
    °æ»ç¿¡ÄÚ¿µ»ó
  • gradient refocused imaging
    °æ»çÀçÃÊÁ¡¿µ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
OHA oral hypoglycemic agents
ACBaE air contrast barium enema
ACBE air contrast barium enema
CC calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card...
CCT carotid compression tomography; central conduction time; cerebrocranial trauma; chocolate-coated tab...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
MRI Magnetic Resonance Image
(1)H-MRS Magnetic Resonance Spectroscopy
MRT Magnetic Resonance Tomography
MRI Magnetic resonance
MRM Magnetic resonance microscopy
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
neoplasm: gallium imaging <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications
(12 Dec 1998)
dark field imaging <microscopy> Using a single diffracted beam to form the image in a transmission electron microscope. This causes all regions of the specimen not of the same crystal structure and orientation as the region which produced the diffracted beam to be represented as very dark in the final image, allowing phase differentiation visually in the transmission electron microscope.
(05 Aug 1998)
diagnostic imaging Any visual display of structural or functional patterns of organs or tissues for diagnostic evaluation. It includes measuring physiologic and metabolic responses to physical and chemical stimuli, as well as ultramicroscopy.
(12 Dec 1998)
dipyridamole-thallium imaging <radiology> Myocardial perfusion imaging for patients who cannot exercise, dipyridamole, potent coronary vasodilator, dose: 300 mg IV, side effects relieved by aminophyllin, thallium given when: symptomatic, HR increased 10 bpm, diastolic BP decreased 10 mm Hg, 45 min after PO dose
(12 Dec 1998)
imaging Radiological production of a clinical image using X-rays, ultrasound, computed tomography, magnetic resonance, radionuclide scanning, thermography, etc.; especially, cross-sectional imaging, such as ultrasonography, CT, or MRI.
Origin: see image
(05 Mar 2000)
imaging department The diagnostic radiology department.
See: imaging, radiology.
(05 Mar 2000)
inflammation: gallium imaging <radiology> Pathophysiology: leakage of protein-bound Ga-67 into extracellular space secondary to increased capillary permeability, Ga-67 is preferentially bound to nonviable PMNs and macrophages, leukocyte incorporation (rich in lactoferrin), bacterial uptake (siderophores), inflammtory tissue stimulates lactoferrin production for chronic abdominal inflammation: 67% sensitivity; 64% specificity; 13% false negatives; 5% false positive, dose: 5 mCi; imaging: 24, 48, 72 hours, diffuse uptake in peritonitis, localised uptake in acute pyogenic abscess, phlegmon, acute cholecystitis, acute pancreatitis, acute gastritis, diverticulitis, inflammatory bowel disease, surgical wound, pyelonephritis, perinephric abscess see: gallium indications, gallium vs. Indium
(12 Dec 1998)
echo-planar imaging A type of magnetic resonance imaging that uses only one nuclear spin excitation per image and therefore can obtain images in a fraction of a second rather than the minutes required in traditional mri techniques. It is used in a variety of medical and scientific applications.
(12 Dec 1998)
through transfer imaging The production of an ultrasound image by detection and analysis of sound on the opposite side of the body from the emitting transducer.
Synonym: through transfer imaging.
(05 Mar 2000)
thyroid imaging <radiology> Tc-99m pertechnetate 6 mCi, I-123 sodium iodide 200 - 400 uCi PO
(12 Dec 1998)
transfer imaging The production of an ultrasound image by detection and analysis of sound on the opposite side of the body from the emitting transducer.
Synonym: through transfer imaging.
(05 Mar 2000)
ultrasound imaging <investigation, procedure> A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer.
(12 May 1997)
kidney: gallium imaging <radiology> 10-20% of Ga-67 excreted via GU tract; no renal activity after 24hrs abnormal uptake (images at 48-72 hrs): tumour, primary renal tumour (variable uptake), lymphoma/leukaemia, metastases (e.g., melanoma), inflammation, acute pyelonephritis (88% sensitivity); abscess, lobar nephroma, others, collagen vascular disease, vasculitis, Wegener granulomatosis, amyloidosis, haemochromatosis, hepatic failure, antineoplastic drugs, transplant rejection: acute, chronic, ATN see also: gallium: indications
(12 Dec 1998)
liver metastases: ultrasound imaging <radiology> Echogenic (25%), colonic carcinoma, hepatocellular carcinoma, treated breast carcinoma mixed echogenicity (37.5%), breast carcinoma, rectal carcinoma, lung carcinoma, stomach carcinoma, anaplastic cancer, cervical carcinoma, carcinoid hypoechoic (37.5%), lymphoma, pancreatic carcinoma, cervical carcinoma, lung carcinoma (adenocarcinoma), nasopharyngeal carcinoma see: liver metastases
(12 Dec 1998)
lung: gallium imaging <radiology> Scans at 48 hrs because 50% of normals show activity at 24 hrs, focal uptake, primary pulmonary malignancy, benign disorder: granuloma, abscess, pneumonia, silicosis, multifocal/diffuse uptake, infection, TB: active lesion, miliary TB, rapidly progressive TB pneumonia, PCP: unimpressive symptoms and CXR, CMV, inflammation: sarcoid, interstitial lung disease (pneumoconiosis, idiopathic pulmonary fibrosis, lymphangitic carcinomatosis), radiation pneumonitis, drugs: bleomycin, amiodarone, contrast lymphangiography (in 50%) see: gallium: indications, uptake with normal chest film
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á